Brand Name

XTORO

Generic Name
Finafloxacin
View Brand Information
FDA approval date: March 24, 2026
Classification: Quinolone Antimicrobial
Form: Suspension

What is XTORO (Finafloxacin)?

XTORO® is indicated for the treatment of acute otitis externa with or without an otowick, caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus in patients age 1 year and older. XTORO® is a quinolone antimicrobial indicated for the treatment of acute otitis externa caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Efficacy and Safety of Finafloxacin Otic Suspension, 0.3% for the Treatment of Acute Otitis Externa: Results from two Phase III Randomized Clinical Studies.
Efficacy and Safety of Finafloxacin Otic Suspension, 0.3% for the Treatment of Acute Otitis Externa: Results from two Phase III Randomized Clinical Studies.
Journal: The Annals of otology, rhinology, and laryngology
Published: May 29, 2026
An evaluation of antibiotic options for the treatment of biothreat pathogens.
An evaluation of antibiotic options for the treatment of biothreat pathogens.
Journal: Frontiers in antibiotics
Published: April 14, 2025
Layering vaccination with antibiotic therapy results in protection and clearance of Burkholderia pseudomallei in Balb/c mice.
Layering vaccination with antibiotic therapy results in protection and clearance of Burkholderia pseudomallei in Balb/c mice.
Journal: Infection and immunity
Published: January 30, 2024
View All Latest Advances